10-Q: Castle Biosciences Q2 2026 Financial Update

Castle Biosciences reports Q2 2026 results with revenue growth driven by non-dermatologic tests, though net loss widens.

Summary

• Castle Biosciences reported net revenues of $103.5 million for the three months ended June 30, 2026, a 20.1% increase compared to the same period in 2025.
• For the six months ended June 30, 2026, net revenues were $187.2 million, a 7.5% increase year-over-year.
• The company experienced a net loss of $2.1 million for the three months ended June 30, 2026, compared to a net income of $4.5 million in the prior year period.
• The net loss for the six months ended June 30, 2026, was $16.6 million, an improvement from a net loss of $21.3 million in the prior year period.
• Cash and cash equivalents decreased to $62.1 million as of June 30, 2026, from $116.7 million as of December 31, 2025.
• Marketable investment securities increased to $204.7 million as of June 30, 2026, from $182.8 million as of December 31, 2025.
• Operating expenses increased by 17.9% for the three months and 1.1% for the six months ended June 30, 2026, compared to the respective prior year periods.
• The company's gross margin percentage decreased to 74.9% for the three months ended June 30, 2026, from 77.3% in the prior year period, but increased to 74.0% for the six months ended June 30, 2026, from 63.1% in the prior year period.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the widening net loss in the current quarter and increased operating expenses, despite revenue growth.

Positives

• Net revenues increased by 20.1% to $103.5 million for the three months ended June 30, 2026, driven by a significant increase in non-dermatologic test revenues.
• Non-dermatologic test revenues grew by $25.0 million for the three months and $42.5 million for the six months ended June 30, 2026, primarily due to higher TissueCypher test volumes.
• TissueCypher test report volume increased by 63% for the three months and 61% for the six months ended June 30, 2026, indicating strong commercial adoption.
• DecisionDx-Melanoma test report volume increased by 3% for the three months and 9% for the six months ended June 30, 2026.
• Gross margin percentage improved to 74.0% for the six months ended June 30, 2026, from 63.1% in the prior year period, largely due to lower amortization of acquired intangible assets.
• The company ended the period with $62.1 million in cash and cash equivalents and $204.7 million in marketable investment securities, providing a solid liquidity position.
• AdvanceAD-Tx test received approximately 1,000 and 1,650 orders during the three and six months ended June 30, 2026, respectively, during its limited access launch phase.

Negatives

• The company reported a net loss of $2.1 million for the three months ended June 30, 2026, a significant decrease from a net income of $4.5 million in the prior year period.
• Cost of sales (exclusive of amortization) increased by 34.5% for the three months and 30.1% for the six months ended June 30, 2026, outpacing revenue growth in the three-month period.
• Gross margin percentage decreased to 74.9% for the three months ended June 30, 2026, from 77.3% in the prior year period.
• Dermatologic test revenues decreased by $7.6 million for the three months and $29.5 million for the six months ended June 30, 2026, primarily due to lower DecisionDx-SCC test performance.
• Cash and cash equivalents decreased by $54.6 million during the six months ended June 30, 2026, indicating significant cash burn from operations and investing activities.
• Selling, general and administrative expenses increased by 13.9% for the three months and 12.3% for the six months ended June 30, 2026.

Risks

• The company has a history of net losses and an accumulated deficit of $240.9 million as of June 30, 2026, and may be unable to achieve sustained profitability.
• The loss of Medicare coverage for DecisionDx-SCC in April 2025 has impacted revenues and is expected to continue to do so unless reconsideration requests are approved.
• Unfavorable U.S. and global economic conditions, including inflation, geopolitical conflicts, and potential financial market disruptions, could adversely affect the business.
• The company's revenue depends on obtaining and maintaining favorable coverage and reimbursement policies from third-party payors, which can be subject to change.
• The company is exposed to interest rate risk from its outstanding term debt which bears a floating rate.
• Foreign currency exchange rate risk exists due to a loan receivable and certain equity securities denominated in Swedish Krona (SEK).

Future Outlook

The company expects expenses to increase substantially due to investments in clinical studies, commercialization strategies, new product development, hiring of scientific and R&D staff, and operational system enhancements. Future funding requirements will depend on various factors, and the company may need to raise additional capital through equity or debt financings, which could dilute existing stockholders or impose restrictive covenants.

Management Comments

• The company believes its current cash and cash equivalents, marketable investment securities, and anticipated revenue are sufficient to meet cash requirements for at least the next 12 months.
• The company expects to continue incurring R&D expenses through ongoing investments in pipeline initiatives and seeking opportunities to build evidentiary support and new tests.
• The company believes that expanding reimbursement is an important indicator of the value of its products and depends on demonstrating this value to payors.
• The company expects cost of sales expenses to continue to increase as it hires additional laboratory personnel and resources to support operational growth and higher test volumes.

Industry Context

StockSavvy.ai notes that Castle Biosciences operates in the competitive molecular diagnostics market, facing challenges related to reimbursement, evolving clinical guidelines, and the need for continuous innovation. The company's focus on specific dermatologic and gastrointestinal conditions positions it within niche but growing segments of the healthcare industry.

Comparison to Industry Standards

• The company's gross margin percentage of 74.9% for the three months ended June 30, 2026, is strong for the diagnostics industry, though it saw a slight decrease from the prior year.
• The significant increase in non-dermatologic test revenues, particularly TissueCypher, aligns with a broader industry trend towards more personalized and predictive diagnostics.
• The company's investment in R&D, while increasing expenses, is crucial for staying competitive in the rapidly advancing field of molecular diagnostics, similar to peers like Guardant Health and Exact Sciences.

Legal Proceedings

• The company is cooperating with a subpoena from the U.S. Department of Health and Human Services, Office of Inspector General, seeking documents and information concerning claims submitted for payment under federal healthcare programs for tests from January 1, 2015, to the present.

Stakeholder Impact

• Shareholders may be impacted by the widening net loss in the current quarter and the potential for future dilution if capital is raised through equity offerings.
• Employees may be impacted by continued investment in R&D and commercialization, potentially leading to increased workload and opportunities.
• Clinicians and patients will continue to benefit from the company's diagnostic tests, with potential for expanded offerings like AdvanceAD-Tx.
• Third-party payors, including Medicare, are critical stakeholders, as their coverage and reimbursement decisions significantly impact the company's revenue recognition and financial performance.

Next Steps

• Continue commercialization strategy for current and future products.
• Execute clinical studies to support product adoption and reimbursement.
• Develop and commercialize additional tests, potentially through acquisitions.
• Seek favorable coverage and reimbursement decisions from third-party payors.
• Expand availability of the AdvanceAD-Tx test in a phased manner throughout the remainder of 2026.
• Continue to invest in expanding the Pittsburgh laboratory operations for TissueCypher testing capacity.

Key Dates

Recommendation

While revenue growth is positive, the widening net loss in the current quarter and increased operating expenses warrant a cautious approach. The company's reliance on reimbursement and the potential impact of regulatory changes on key products like DecisionDx-SCC present ongoing risks. Continued monitoring of revenue growth, cost management, and reimbursement developments is advised.

Keywords

Castle Biosciences, 10-Q, Diagnostics, Molecular Diagnostics, Dermatology, Gastroenterology, Oncology, Revenue